Adia Nutrition, Inc. revenue by segment ADIA

Annual Quarterly

Adia Nutrition, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Adia Labs at $448,888, 64% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Biologics at $289,588, 41% of the total.

USD in millions. The percent under a figure is the change from the year before.

FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Revenue
—
1
Operating segments
Adia Labs
—
0
share 64.1%
Adia Med
—
0
share 35.1%
Corporate
—
0
share 0.3%
Sales mix
Biologics
—
0
share 41.3%
Medical Procedures
—
0
share 35.1%
Procedures
—
0
share 31.1%
Sales Of Ancillary Products
—
0
share 0.1%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
ADIA (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Winter Park, FL
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1160420
Former names
Adia Nutrition, Inc. (until Aug 24, 2026); PivX Solutions, Inc. (until Jul 17, 2013); DRILLING INC (until Apr 21, 2004)

Other Medicinal Chemicals & Botanical Products companies

All 43 Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.